SEC Form 3 · accession 0001192482-15-000161
COLLEGIUM PHARMACEUTICAL, INC · COLL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eran Nadav
Director
Period of report
May 6, 2015
Accepted (ET)
May 6, 2015 · 4:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001267565
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| No securities beneficially ownedF1,F2 | holding | — | — | — | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Dr. Eran Nadav is a TPG Partner. TPG is affiliated with TPG Biotechnology Partners IV, L.P., which holds shares of Series D Convertible Preferred Stock of Collegium Pharmaceutical, Inc. (the "Issuer"), which are convertible into shares of Common Stock, par value $0.001 per share, of the Issuer.
- F2Dr. Nadav disclaims beneficial ownership of all of the securities that are or may be beneficially owned by TPG Biotechnology Partners IV, L.P. or any of its affiliates. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Dr. Nadav is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer for purposes of Section 16 of the Exchange Act or otherwise.